Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Retroperitoneal sarcoma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Liposarcoma recurs in the abdomen in most patients even after complete surgery.
Neither radiotherapy nor chemotherapy has a proven adjuvant benefit.
Outcomes still depend on referral to a specialist centre before the first operation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Median PFS 12.
Abdominal recurrence-free survival not improved by preoperative radiotherapy; possible benefit in liposarcoma subgroups only.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.